Caribou Biosciences, Inc. announced a strategic shift focusing on its lead oncology programs, CB-010 and CB-011, involving workforce and cost reductions aimed at extending its cash runway into the ...
-- CB-010 ANTLER 2L LBCL Phase 1 dataset expected to include at least six months of follow up on the majority of patients; ongoing interactions with FDA on potential pivotal trial design -- -- CB-011 ...
Most organizations struggle to innovate because they don’t solve the gap between a compelling strategy and consistent ...
Highest priority programs – BEAM-101 and ESCAPE for sickle cell disease and BEAM-302 for alpha-1 antitrypsin deficiency – expected to provide foundation for meaningful value creation Company to ...
Hosted on MSN
Pfizer targets $7.7B in operational efficiency savings by 2027, highlights strategic R&D shifts
CEO Dr. Albert Bourla discussed Pfizer's strategic focus on improving R&D productivity, emphasizing a disciplined approach to advancing its pipeline. The company highlighted the discontinuation of ...
Tsukuba, Japan—The human genome contains approximately 1,600 types of transcription factors responsible for regulating gene activity across more than 400 tissue and cell types. Chromatin ...
– Strategic restructuring includes reduced operating expenses, delivering approximately $400 million in anticipated annual cost savings, and implementing a 36% workforce reduction of approximately 500 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results